FABTECH - Fabtech Tech.
📢 Recent Corporate Announcements
Fabtech Technologies Limited has released the video recording of its earnings conference call held on April 28, 2026. The call focused on the company's audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. This disclosure is in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015. The recording allows investors to review management's detailed commentary on the fiscal year's performance and future outlook.
- Earnings conference call held on April 28, 2026, at 10:00 a.m. IST.
- Discussion covered audited standalone and consolidated results for FY ended March 31, 2026.
- Video recording link made publicly available on the company's official website.
- Compliance filing under SEBI Listing Obligations and Disclosure Requirements.
Fabtech Technologies reported a strong FY26 performance with total income growing 28.4% YoY to ₹431.33 crore and a net profit of ₹38.36 crore. The company's order book stands robust at over ₹900 crore, providing significant revenue visibility for the coming years. Geographically, the UAE and Saudi Arabia remain the largest contributors, while the Kenyan market saw a massive 236% surge in revenue. Notably, the company improved its cash flow position and reduced its debt, strengthening its balance sheet.
- Total Income grew 28.4% YoY to ₹431.33 crore, driven by international turnkey projects in the life sciences sector.
- Consolidated order book reached ₹900+ crore as of March 31, 2026, providing strong revenue visibility.
- Cash and bank balances increased significantly by 495.7% to ₹208.57 crore during the fiscal year.
- Successfully reduced current borrowings from ₹54.09 crore to ₹42.20 crore, improving the debt-to-equity profile.
- Major new project wins include a ₹65.5 crore animal vaccine project in Saudi Arabia and a ₹63.6 crore facility in West Africa.
Fabtech Technologies Limited has reported its audited financial results for the fiscal year ending March 31, 2026, alongside a dividend announcement. The Board has recommended a final dividend of ₹0.60 per equity share, pending shareholder approval. Strategically, the company is expanding its global footprint by authorizing the opening of a step-down subsidiary in the Sultanate of Oman. Financial data indicates strong performance from international operations, with a foreign subsidiary contributing ₹173.78 crore to annual revenue and ₹12.74 crore to net profit.
- Recommended a final dividend of ₹0.60 per equity share (6% of face value) for FY 2025-26.
- Approved the establishment of a new step-down subsidiary in the Sultanate of Oman to drive international growth.
- Foreign subsidiary reported annual revenue of ₹17,378.57 Lakhs and a net profit of ₹1,274.06 Lakhs.
- Foreign subsidiary assets reached ₹15,589.55 Lakhs as of March 31, 2026.
- Consolidated results include a share of profit from associates amounting to ₹33.52 Lakhs for the full year.
Fabtech Technologies Limited has scheduled its earnings conference call for April 28, 2026, at 10:00 AM IST to discuss the audited financial results for the quarter and full year ended March 31, 2026. The call will feature a management discussion followed by an interactive Q&A session. Key leadership, including the Promoter, CEO, and Chief Growth Officer, will be present to address investor queries. This meeting is a standard regulatory procedure to provide transparency regarding the company's annual performance.
- Earnings conference call scheduled for Tuesday, April 28, 2026, at 10:00 AM IST.
- The call will cover audited financial results for the quarter and full year ended March 31, 2026 (FY26).
- Senior management including Promoter Aasif Khan and CEO Ashwani Singh will participate.
- The session is organized by AKMIL Strategic Advisors and includes an interactive Q&A session.
- Investors can register for the audio/video call through the provided registration links.
Fabtech Technologies has announced the appointment of Ms. Rupal Dhiren Haria as an Additional Non-Executive, Independent Director for a five-year term starting April 03, 2026. This appointment follows the completion of the tenure of Ms. Aparna Narendra Sharma, who will step down on April 02, 2026. Ms. Haria is a Chartered Accountant with over 20 years of experience in taxation and auditing. Consequently, the company has reconstituted its Audit, Nomination & Remuneration, and Stakeholder Relationship Committees to maintain regulatory compliance.
- Appointment of Ms. Rupal Dhiren Haria as Independent Director for a 5-year term effective April 03, 2026.
- Completion of tenure for Ms. Aparna Narendra Sharma as Independent Director on April 02, 2026.
- Ms. Rupal Haria brings over 20 years of experience as a Chartered Accountant specializing in corporate taxation and auditing.
- Reconstitution of three key board committees, with Ms. Haria appointed as Chairperson for the NRC and Stakeholder Relationship Committee.
Fabtech Technologies Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting April 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations for the upcoming audited financial results for the quarter and year ending March 31, 2026. The trading window will remain closed until 48 hours after the financial results are declared. The company will announce the specific date for the board meeting to approve these results in due course.
- Trading window closure begins on Wednesday, April 1, 2026.
- Closure pertains to the audited financial results for the quarter and year ending March 31, 2026.
- Window to reopen 48 hours after the official declaration of financial results.
- Compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.
Fabtech Technologies has announced that its board approved the carry-forward of unutilized IPO proceeds from the current financial year 2025-26 to FY 2026-27. The company confirmed that there has been no deviation in the utilization of funds from the objects stated in its prospectus dated October 02, 2025. This indicates a delay in the planned capital expenditure or project execution timeline originally envisioned for the current fiscal year. The funds remain earmarked for their original purposes in compliance with SEBI regulations.
- Board approved carry-forward of IPO proceeds from FY 2025-26 to FY 2026-27.
- Confirmed zero deviation in fund utilization compared to the prospectus dated October 02, 2025.
- Unutilized funds are strictly intended for objects stated in the original IPO filing.
- The board meeting concluded at 12:45 p.m. on March 24, 2026.
Fabtech Technologies Limited successfully conducted two separate investor interactions on March 10, 2026, to discuss business operations and strategic outlook. The company participated in the 'Bharat Connect Conference – Rising Stars 2026' hosted by Arihant Capital via video conferencing. Additionally, officials attended the 'Vivro Corporate Connect – Investors’ Meet 2026' physically in Mumbai. The discussions focused on market opportunities and future growth strategies based on publicly available information.
- Participated in the Bharat Connect Conference hosted by Arihant Capital on March 10, 2026.
- Attended the Vivro Corporate Connect physical meeting in Mumbai starting at 9:00 AM IST.
- Discussions covered business operations, market opportunities, and future strategic directions.
- Company confirmed that no unpublished price-sensitive information (UPSI) was shared during the meetings.
Fabtech Technologies Limited has responded to inquiries from the NSE and BSE regarding a significant spurt in trading volume and price movement. The company officially stated that there is no pending price-sensitive information or undisclosed announcements that could have triggered this activity. Management clarified that the recent volatility is purely market-driven and not linked to any internal corporate developments. The filing was made on March 11, 2026, to ensure transparency and safeguard investor interests as per SEBI regulations.
- Company responded to exchange queries regarding unusual volume on March 11, 2026
- Management confirms no undisclosed material information exists under Regulation 30
- Stock price and volume movements are attributed entirely to market forces
- Company reaffirms commitment to timely disclosure of all future price-sensitive events
Fabtech Technologies has responded to a clarification sought by the National Stock Exchange (NSE) regarding the signing of its financial results for the quarter ended December 31, 2025. The company confirmed that the results, approved on February 02, 2026, were signed by authorized personnel including Executive Director Hemant Anavkar and Non-Executive Director Amjad Arbani. The company cited SEBI Regulation 33(2)(b), which permits any board-authorized director to sign financial statements. This clarification addresses procedural queries raised by the exchange to ensure the results are officially recorded without further delay.
- NSE sought clarification on February 27, 2026, regarding the signing protocol of Q3 FY26 results.
- Company confirmed results were approved in a Board Meeting held on February 02, 2026.
- Board Resolution authorized Mr. Hemant Anavkar (ED) and Mr. Amjad Arbani (NED) to sign the results.
- The company maintains full compliance with SEBI Regulation 33(2)(b) regarding signatory requirements.
- The clarification aims to resolve the exchange's query and finalize the recording of the financial results.
Fabtech Technologies Limited has scheduled a one-on-one interaction with investors and analysts on March 12, 2026. The meeting is set to take place virtually via video conference starting at 2:30 p.m. IST. The company has explicitly stated that the discussions will be based on publicly available information and no unpublished price-sensitive information (UPSI) will be shared. This meeting is a routine part of the company's investor relations activities under SEBI regulations.
- One-on-one virtual meeting scheduled for Thursday, March 12, 2026, at 2:30 p.m. IST.
- Interaction will be conducted through video conferencing with various analysts and investors.
- Company confirms that no unpublished price-sensitive information (UPSI) will be discussed.
- The meeting is subject to change based on the exigencies of the participants or the company.
Fabtech Technologies Limited has scheduled a virtual one-on-one meeting with analysts and investors on March 12, 2026, at 2:30 p.m. IST. The interaction is intended to discuss the company's performance based on publicly available information, ensuring compliance with SEBI regulations regarding price-sensitive data. This routine engagement highlights the management's effort to maintain transparency with the investment community. No unpublished price-sensitive information (UPSI) is expected to be disclosed during this session.
- One-on-one virtual meeting scheduled for March 12, 2026, at 2:30 p.m. IST.
- Interaction will be conducted via video conference with institutional analysts and investors.
- Discussions will strictly adhere to publicly available information to avoid UPSI disclosure.
- The notification was filed under Regulation 30 of SEBI (LODR) Regulations, 2015.
Fabtech Technologies Limited has announced a virtual interaction with investors and analysts scheduled for March 10, 2026, at 4:00 p.m. IST. The company will be participating in the 'Bharat Connect Conference – Rising Stars 2026' organized by Arihant Capital. This group meeting is intended to engage with the investment community using publicly available information. No unpublished price-sensitive information is expected to be disclosed during the session.
- Investor meeting scheduled for March 10, 2026, at 4:00 p.m. IST
- Participation in the Bharat Connect Conference – Rising Stars 2026 hosted by Arihant Capital
- The interaction will be conducted via a virtual group meeting format
- Company confirms discussions will be limited to publicly available information only
Fabtech Technologies Limited has announced its participation in the CVOCA Investocraft 2026 event on February 28, 2026. The physical group meeting with investors and analysts will commence at 8:30 a.m. IST at Sahara Star, Mumbai. The company stated that discussions will be based strictly on publicly available information, ensuring no unpublished price-sensitive information is shared. This event serves as a platform for the management to engage with the broader investment community.
- Scheduled physical group meeting with investors on February 28, 2026, at 8:30 a.m. IST
- Participation in the CVOCA Investocraft 2026 event held at Sahara Star, Mumbai
- Company officials to interact with analysts and investors regarding general business outlook
- Strict adherence to sharing only publicly available information during the interaction
- Intimation provided under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations
Fabtech Technologies reported temporary softness in Q3 FY26 revenue due to shipment-based accounting, with ₹20.3 crores of revenue deferred to Q4 after material was held at the port. The company maintains a robust outstanding order book of ₹926 crores as of January 31, 2026, primarily driven by export demand in Africa and the Middle East. Management highlighted a significant 'hot lead bank' pipeline valued at approximately $455 million. The company is also streamlining its portfolio by exiting TSA Process Equipments within the current financial year to focus on its core life-sciences infrastructure platform.
- Outstanding order book reached ₹926 crores as of January 31, 2026, with a heavy focus on international markets.
- Revenue of ₹20.3 crores was deferred from Q3 to Q4 due to timing of shipments and port delays.
- Management identified a robust pipeline of potential orders (hot lead bank) worth approximately $455 million.
- Company plans to exit its investment in TSA Process Equipments within the 2025-26 financial year.
- Typical project execution timelines range from 9 to 18 months, with efforts underway to accelerate delivery.
Financial Performance
Revenue Growth by Segment
Turnkey engineering solutions for life sciences grew 43.7% in FY25 to INR 322.47 Cr. Approximately 30% of revenue is derived from in-house manufactured products (Process, Air, and Water systems), while 70% comes from integrated project management and third-party equipment supply.
Geographic Revenue Split
The company operates in 62 countries with a strong presence in 22 active markets. Key growth regions include MENA (Middle East and North Africa), GCC, and ECO Zone, which are driving revenue through increased investments in local pharmaceutical self-reliance.
Profitability Margins
PAT margins improved from 12.03% in FY24 to 15.48% in FY25. However, operating margins saw a decline from 16.23% in FY24 to 12.73% in FY25 due to project mix and cost structures. H1 FY26 Net Profit stood at INR 21.98 Cr, a 101.6% YoY increase.
EBITDA Margin
EBITDA margin for H1 FY26 was 14.7%, reflecting a significant improvement from the 12.73% reported in FY25. The company targets a sustainable annual EBITDA range of 12-15% despite quarterly lumpiness in project execution.
Capital Expenditure
Fabtech follows an asset-light model and is not capital-intensive. The company successfully raised INR 230 Cr through an IPO fresh issue in October 2025, primarily to fund working capital requirements and business expansion rather than heavy manufacturing assets.
Credit Rating & Borrowing
Crisil reaffirmed ratings at 'Crisil BBB+/Stable' for long-term and 'Crisil A2' for short-term facilities. Working capital utilization averaged 70% over the 7 months ended June 2025, with an adjusted debt-to-networth ratio of 0.39x as of March 2025.
Operational Drivers
Raw Materials
Key raw materials include stainless steel, specialized components for HVAC systems, and water purification filters. Raw material costs (Cost of Material) accounted for 54.1% of total income in FY25, amounting to INR 181.86 Cr.
Import Sources
Not explicitly disclosed, but the company operates in 62 countries and sources components globally to support its international turnkey projects in regions like MENA and GCC.
Capacity Expansion
The company operates an asset-light model where revenue is driven by project engineering and design. Management stated they can double revenue (X to X+Y) with the same core team by increasing procurement and engineering oversight without significant gross block expansion.
Raw Material Costs
Cost of materials increased from INR 121.51 Cr in FY24 to INR 181.86 Cr in FY25, representing a 49.6% increase. Procurement is managed through a 'single window' model to ensure speed and compliance for pharmaceutical clients.
Manufacturing Efficiency
The company maintains ISO-certified operations with a team of 180+ members, including 94+ qualified engineers, focusing on 'execution excellence' to maintain a 9% quarterly growth trajectory.
Strategic Growth
Expected Growth Rate
20%
Growth Strategy
Growth will be achieved by leveraging the INR 904.42 Cr order book (as of July 2025), expanding the 'single window' turnkey model in emerging pharmaceutical markets, and focusing on nations seeking 'medicinal independence' through local manufacturing capacity.
Products & Services
Turnkey pharmaceutical plants, Cleanrooms, HVAC systems, Water for Injection (WFI) systems, Pure Water distribution systems, and Precision Process equipment for biotech and healthcare.
Brand Portfolio
FABTECH, FABL International Technologies, FT Institutions, Fabtech Technologies LLC, FTS Cleanrooms Systems.
New Products/Services
The company is expanding into high-margin capex projects and integrated automation for life sciences, aiming for a 9% sequential growth in the project pipeline.
Market Expansion
Targeting deeper penetration in MENA, GCC, and ECO Zone regions where governments are subsidizing healthcare infrastructure to achieve self-reliance.
Strategic Alliances
The group consolidates operations with subsidiaries like FABL International and FTS Cleanrooms Systems to provide a unified global engineering service.
External Factors
Industry Trends
The industry is shifting toward 'local medicinal independence' in emerging markets. Global pharmaceutical engineering is growing as companies upgrade facilities to meet stringent USFDA and EU GMP compliance standards.
Competitive Landscape
Competes primarily with European engineering firms. Fabtech positions itself as a more cost-effective, integrated alternative with faster execution speeds.
Competitive Moat
Moat is built on a 3-decade legacy, in-house manufacturing of critical Air/Water/Process systems (30% of project value), and a 'single window' model that ensures faster regulatory compliance than Western competitors.
Macro Economic Sensitivity
Highly sensitive to pharmaceutical industry capex cycles and government healthcare spending in emerging markets.
Consumer Behavior
Increased demand for biotech and life sciences infrastructure following global health crises, driving a shift toward more complex, automated manufacturing facilities.
Geopolitical Risks
Exposure to volatile international markets; however, management mitigates this by diversifying across multiple regions so that if one market slows, others (like the ECO zone) can compensate.
Regulatory & Governance
Industry Regulations
Operations must comply with global pharmaceutical standards including USFDA, EU GMP, Saudi FDA, and UK MHRA. Failure to meet these standards would halt project handovers.
Taxation Policy Impact
Effective tax rate for FY25 was approximately 23.1% (INR 13.98 Cr tax on INR 60.43 Cr PBT).
Risk Analysis
Key Uncertainties
Quarterly earnings volatility due to the 'lumpy' nature of project-based billing, which can see margins swing from 8% to 25% between quarters.
Geographic Concentration Risk
Significant revenue concentration in emerging markets (MENA/GCC), making the company vulnerable to regional geopolitical instability.
Third Party Dependencies
70% of turnkey project components are sourced from third-party vendors, creating risks related to quality control and supply chain delays.
Technology Obsolescence Risk
Risk of shifting to advanced biotech manufacturing processes; mitigated by in-house design and engineering teams focusing on precision process systems.
Credit & Counterparty Risk
High working capital intensity with a focus on debtor collection as a key rating sensitivity factor. Cash and bank balance stood at INR 35.19 Cr as of March 2025.